There were a couple of surprise planned departures and relocations revealed at European pharmaceutical majors, first at Germany’s Bayer and also at France’s Sanofi. 4 June 2014
UK-based monoclonal antibody biopharmaceutical company Kymab has announced the appointment of Steve Arkinstall as Chief Scientific Officer and Nigel Clark as Vice President and Head of Business Development. 3 June 2014
Swiss pharma major Novartis has announced the appointment of Bruno Strigini as president of Novartis Oncology, effective June 1, replacing Herve Hoppenot, who quit the post early this year to become chief executive of USA-based Incyte Corp. 1 June 2014
US pharma giant Pfizer has announced that Morris Birnbaum has joined the company as Chief Scientific Officer for Cardiovascular and Metabolic Disease Research. Dr Birnbaum will report directly to Rod MacKenzie, Group Senior Vice President and Head of PharmaTherapeutics Research & Development. 30 May 2014
US-based biopharmaceutical company Nektar Therapeutics (Nasdaq: NKTR) has announced that Ivan Gergel will serve as the Company's new Senior Vice President, Drug Development & Chief Medical Officer effective immediately. 19 May 2014
US drugmaker AbbVie (NYSE: ABBV) has named Michael Severino as Executive Vice President, Research and Development (R&D) and Chief Scientific Officer. 16 May 2014
US generics major Actavis (NYSE: ACT) has announced the proposed senior management team that will lead the company pending the successful close of the acquisition of Forest Laboratories, anticipated mid-year. 14 May 2014
US biotech firm Amgen has announced the appointment of Steven Galson to the position of senior vice president, Global Regulatory Affairs and Safety, effective May 19. 14 May 2014
UK-based biopharmaceutical company Ario Pharma has announced the appointment of Professor Peter Barnes and Professor Wisia Wedzicha to its Scientific Advisory Board with immediate effect. 12 May 2014
Germany’s Merck (MRK: DE) has appointed Marcus Kuhnert as Group Chief Financial Officer. Mr Kuhnert will become a member of Merck’s Executive Board with unlimited personal liability as of August 1, 2014. 9 May 2014
US-based Eleven Biotherapeutics (Nasdaq: EBIO), a clinical-stage biopharmaceutical company developing protein therapeutics to treat eye diseases, has announced the appointment of Gary Sternberg as Executive Vice President of Corporate and Business Development. 8 May 2014
Stalicla, a privately-held Swiss biotech, today announced that Dr Paulo Fontoura will be joining its drug development team as chief scientific and clinical development advisor. 19 September 2024
US contract development and manufacturing organization (CDMO) BioCentriq has appointed Syed Husain as its new chief executive (CEO), and as a member of the board of directors. 19 September 2024
Structure Therapeutics, a specialist in small molecule treatments for metabolic and pulmonary diseases, has announced key leadership appointments. 18 September 2024
Californian biopharma 89bio, a company focused on the development and commercialization of innovative therapies for the treatment of liver and cardiometabolic diseases, has announced an important appointment. 17 September 2024
British biotech IMU Biosciences has announced key changes to its leadership team as it looks to grow in the field of precision medicine. 17 September 2024
Ohio, USA-based Trailhead Biosystems has appointed Josh Snow as its new chief commercial officer, as the company moves to expand its presence in the commercial market with its iPSC-derived human cell products. 16 September 2024
Under pressure from certain shareholders, autoimmune diseases specialist Aurinia Pharmaceuticals on Friday said it has restructured its board of directors. 14 September 2024
US neurological diseases specialist Ovid Therapeutics has announced the promotion of Meg Alexander to president and chief operating officer (COO). 12 September 2024
French cancer focused biotech Transgene has appointed two seasoned leaders in oncology who will be instrumental in advancing the company’s innovative immunotherapy programs 10 September 2024
Italy-based biotech AAVantgarde Bio has appointed Jayashree Sahni as its new chief medical officer, replacing Naveed Shams, who has held the role since 2022. 10 September 2024
California’s Lykos Therapeutics is still trying to regroup after being rocked by the US Food and Drug Administration’s (FDA) rejection of midomafetamine (MDMA) capsules for the treatment of post-traumatic stress disorder (PTSD). 6 September 2024
Biosimilar-focused biopharmaceutical company and contract development and manufacturing organization (CDMO) Tanvex BioPharma has named Stephen Lam its new chief executive (CEO). 5 September 2024
Novocure (Nasdaq: NVCR) has announced that chief executive Asaf Danziger will retire at the end of 2024, with current chief financial officer Ashley Cordova set to succeed him as CEO. 4 September 2024